Evelo Biosciences, Inc.

NASDAQ:EVLO

0 (USD) • At close January 6, 2025
Bedrijfsnaam Evelo Biosciences, Inc.
Symbool EVLO
Munteenheid USD
Prijs 0.001
Beurswaarde 9,491
Dividendpercentage 0%
52-weken bereik 0 - 0.075
Industrie Biotechnology
Sector Healthcare
CEO Dr. Balkrishan Gill Ph.D.
Website https://www.evelobio.com

An error occurred while fetching data.

Over Evelo Biosciences, Inc.

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as

Vergelijkbare Aandelen

Elevation Oncology, Inc. logo

Elevation Oncology, Inc.

ELEV

0.839 USD

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NRXP

3.51 USD

Daré Bioscience, Inc. logo

Daré Bioscience, Inc.

DARE

3.34 USD

Passage Bio, Inc. logo

Passage Bio, Inc.

PASG

0.764 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)